Tripeptide derivatives for the treatment of postlesional...

Details Tripeptide derivatives for the treatment of postlesional... Tripeptide derivatives for the treatment of postlesional...

2007-01-16

2007-01-16

Gupta, Anish (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

10635808

ABSTRACT:
The invention relates to the use of specific tripeptides for the treatment of postlesional diseases of ischemic, traumatic or toxic origin. The tripeptide derivatives satisfy formula (I), wherein X represents OH, (C1-5)alkoxy, NH2, NH—C1-5-alkyl, N(C1-5alkyl)2; R1is a residue derived from any of the amino acids Phe, Tyr, Trp, Pro, each of which may optionally be substituted by a (C1-5) alkoxy group, a (C1-5) alkyl group or a halogen atom, and Ala, Val, Leu, or Ile; R2is a residue which is derived from any of the amino acids Gly, Ala, Ile, Val, Ser, Thr, His, Arg, Lys, Pro, Glu, Gln, pGlu, Asp, Leu and Asn; R3and R4independently represent H, OH, (C1 –C5) alkyl, or (C1-5)alkoxy, provided that R3and R4are not both OH or (C1-5)alkoxy; R5represents H, OH, (C1-5)alkyl or (C1-5)alkoxy; and wherein R0preferably represents a cinnamoyl residue; or pharmaceutically acceptable salts thereof.

REFERENCES:
patent: 4985428 (1991-01-01), Carenzi et al.
patent: 5043346 (1991-08-01), Hock et al.
patent: 5212158 (1993-05-01), Vandai
patent: 5840838 (1998-11-01), Hensley et al.
patent: 5973111 (1999-10-01), Bemis et al.
patent: 6080848 (2000-06-01), Henrichwark et al.
patent: 6156572 (2000-12-01), Bellamkonda et al.
patent: 6235929 (2001-05-01), Powers
patent: 6645518 (2003-11-01), Tedeschi et al.
patent: 0316218 (1989-05-01), None
patent: 0446706 (1991-09-01), None
patent: 0446706 (1991-09-01), None
patent: 1018341 (2000-07-01), None
patent: 1231279 (2002-08-01), None
patent: 04-005240 (1992-01-01), None
patent: WO 88/09604 (1988-12-01), None
patent: WO 92/11850 (1992-07-01), None
patent: WO 92/13549 (1992-08-01), None
patent: WO 96/41638 (1996-12-01), None
patent: WO 98/14202 (1998-04-01), None
patent: WO 01/28578 (2001-04-01), None
patent: WO 01/28578 (2001-04-01), None
patent: WO 01/34828 (2001-05-01), None
patent: WO 01/68114 (2001-09-01), None
patent: WO 02/062373 (2002-08-01), None
patent: WO 02/062373 (2002-08-01), None
patent: WO 02/062828 (2002-08-01), None
patent: WO 02/062828 (2002-08-01), None
del Zoppo et al. Trends and Future Developments in the Pharmacological Treatment of Acute Ischaemic Stroke. Drugs. Jul. 1997, vol. 54, No. 1, pp. 9-38.
Kan. Current and future approaches to therapy of Alzheimer's disease. Eur J Med Chem 1992, vol. 27, pp. 565-570.
Nabeshima et al., Staurosporine, a protein kinase inhibitor, attenuates basal forebrain-lesion-induced amnesia and cholinergic neuronal deficit. Neuroscience Letters 1990 vol. 122, pp. 13-16.
Amnesia: Online References For Health Concerns. Accessed online via http://www.lef.org/protocols/prtcl-007.shtml on May 4, 2005. pp. 1-2.
Definition of ‘shock’: http://www.answers.com/shock, accessed online Dec. 8, 2005, 1 page.
Definition and thesaurus of ‘impact’: http://www.answers.com/impact, accessed online Dec. 10, 2005, 2 pages.
Definition of ‘trauma’: http://www.answers.com/trauma, accessed online Dec. 10, 2005, 1 page.
Faden, A.I., et al., “Effect of TRH analogs on neurologic recovery after experimental spinal trauma,”Neurology, 35:1331-1334 (1985).
Geschwind, M., et al., “Detection of apoptotic or necrotic death in neuronal cells by morphological, biochemical, and molecular analysis,” inApoptosis Techniques and Protocols, J. Poirier, ed., 1997, pp. 13-31.
Guiloff, R.J., “Thyrotropin releasing hormone and motorneurone disease”,Reviews in the Neurosciences, 1:201-219 (1987).
Kurtz, A.F., “Praktische Diagnostik,” inAktuelles Wissen Hoechst, Alzheimer-Patienten erkennen und behandeln, Hoechst AG, publisher (Munich, Germany, 1995), 68-69.With partial translation.
Rapin, J.R., “Les nootropes: propiétés pharmacologiques du piracétam et indications thérapeutiques,”La Lettre du Pharmacologue, 6(5):108-111 (1992).With partial translation.
Sarti, G., et al., “TRH-analogues: A possible treatment for symptoms of dementia in elderly patients?”,Archives of Gerontology and Geriatrics, 12:173-177 (1991).
Szirtes, T., et al., “Synthesis of thyrotropin-releasing hormone analogues. 1. Complete dissociation of central nervous system effects from thyrotropin-releasing actvity,”J. Med. Chem. 27:741-745 (1984).
Beyer, H., and Walter, W.,Handbook of Organic Chemistry, by S. Hirzel Verlag, Stuttgard (English translation of the 22ndedition ofLehrbuch der Organischen Chemie) (1996), pp. 827-838.
Blundell, T.L., et al., “Knowledge-based protein modelling and design”,Eur. J. Biochem., 172:513-520 (1988).
Cheesebeuf, M., et al., “Rat liver epithelial cell cultures in a serum-free medium: primary cultures and derived cell lines expressing differentiated functions”,In Vitro, 20(10):780-795 (1984).
Clark, M.C., et al., “Validation of the general purpose Tripos 5.2 force field”,J. Comp. Chem., 10(8):982-1012 (1999).
De Pooter, H., et al., “N-acylamino acids and peptides IV the synthesis of N-cinnamyl-, N-p.coumaryl- and N-caffeyl-glycine and -glycyl-L-phenylalanine”,Bull. Soc. Chim. Belg., 85(9):647-656 (1976). XP008015013.
Faden, A.I., et al., “Novel TRH analog improves motor and cognitive recovery after traumatic brain injury in rodents”,Amer. J. Physiology277(4, pt. 2):R1196-R1204 (1999),Chem. Abstr. 132:31033 XP002207513, XP008014976.
Faden, A.I., et al., “Structure-activity relationships of TRH analogs in rat spinal cord injury”,Brain Research, 448:287-293 (1988). XP008015202.
Gasteiger, J., et al., “Iterative partial equalization of orbital electronegativity—a rapid access to atomic charges”,Tatrahedron, 36:3219-3238 (1980).
Hagg, T., et al., “Delayed treatment with nerve growth factor reverses the apparent loss of cholinergic neurons after acute brain damage”,Exp. Neurol., 101:303-312 (1988).
Jones, D.T., et al., “A new approach to protein fold recognition”,Nature, 358:86-89 (Jul. 1992).
Jones, D.T., “Protein secondary structure prediction based on position-specific scoring matrices”,J. Mol. Biol., 292(2):195-202 (1999).
Kansy, M., et al. “Physicochemical High Throughput Screening: Parallel Artificial Membrane Permeation Assay in the Description of Passive Absorption Processes”,J. Med. Chem., 41(7):1007-1010 (Mar. 26, 1998).
Khuebachova, M., et al., “Mapping the C terminal epitope of the Alzheimer's disease specific antibody MN423”,J. Immunol. Methods(Elsevier Amsterdam, NL) 262(1-2):205-215 (2002). XP004352190.
Laskowski, R.A., et al., “Procheck: a program to check the stereochemical quality of protein structures”,J. Appl. Cryst., 26:283-291 (1993).
Le Poncin-Lafitte, M., et al., “Sound-avoidance conditioning and a mathematical approach to the description of acquisition performance”,Math. Biosciences, 59:249-268 (1982).
Luco, J.M., “Prediction of the brain-blood distribution of a large set of drugs from structurally derived descriptors using partial least-squares (PLS) modeling”,J. Chem.. Inf. Comput. Sci., 39 (2):396-404 (1999).
Parnetti, L., et al., “Posatirelin for the treatment of late-onset Alzheimer's disease: a double-blind multicentre study vs citicoline and ascorbic acid”,Acta Neurol. Scand. 92:135-140 (1995).
Varon, S., et al., “Nerve Growth Factor in CNS Repair”,J. Neurotrama, 11(5) (1994).
Wang. R., et al., “SCORE: A new empirical method for estimating the binding affinity of a protein-ligand complex”,J. Mol. Model., 4:379-394 (1998).
Weiner, S.J., et al., “A new force field for molecular mechanical simulation of nucleic acids and proteins”,J. Am. Chem. Soc., 106:765-784 (1984).
Wiesman, C., et al., “Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor”,Nature, 401:184 (Sep. 9, 1999).

Affiliated with

Also associated with

Rating

Tripeptide derivatives for the treatment of postlesional... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tripeptide derivatives for the treatment of postlesional..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tripeptide derivatives for the treatment of postlesional... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3743317